Marietta, Ohio
ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX)
President and Chief Executive Officer Clarence Smith is pleased at the progress of the health care applications projects the Company has underway. According to Mr. Smith “To that end, ProtoKinetix is continuing to collaborate with some of the most prestigious research institutions. The Company is focusing on research efforts in areas where our AAGP® molecule can significantly impact the success of healthcare outcomes.”
I invite you to click on the links below for more detailed information.
The company plans to introduce video content to its website that will allow for more detailed updates.
Current projects underway include the following:
1. Solutions for Diabetes
Diabetes study currently in a Phase 1 human trial.
Clinicaltrials.gov – Islet Transplantation Using PKX-001.
2. Solutions for blindness from age related macular degeneration
Retinal Cell Replacement study has started Phase 3.
ProtoKinetix Enters into 3rd Phase of Retinal Cell Replacement Therapy Testing at UBC
3. Immunology Studies
a) Cord Blood Stem Cell Storage and Recovery.
b) Cord Blood Stem Cell Transplantation and Engraftment.
c) Monoclonal Antibodies, ‘study completed’.
ProtoKinetix Has Entered into a Research Agreement with The University of British Columbia to Test the Effect of its AAGP® on Monoclonal Antibody Production and Bone Marrow Recovery
4. Solutions Enabling Healthy Survival of Strokes and Heart Attacks
AAGP® Projects for Cardiac/Heart Research includes:
- Suppression of doxorubicin toxicity
- Glucolipotoxity protection
- Endoplasmic reticulum stress mediation
- Ischemic damage repair
- Whole heart ex-vivo preservation
Research being conducted under proprietary MTA agreements include:
5. Solutions enabling increased healthy numbers of life saving stem cells
Material Transfer Agreement ‘A’ includes studies for: ProtoKinetix’ AAGP® Signs a Material Transfer Agreement with a Reputed International Biotech Company
- Cryopreservation of primary mammalian tissue cells
- Enhancing the viability of primary mammalian cells
- Cell lines under stressed culture conditions
6. Material Transfer Agreement ‘B’ includes studies for: ProtoKinetix and Proactive Immune Sciences Announce a Joint Research Collaboration Using AAGP® in Immune Cell Cryopreservation Testing
- Immune Cell Cryopreservation recovery, ‘study completed’
In Our Current Pipeline:
Two studies with an undetermined start dates are Kidney Ischemia and Liver Perfusion.
The company is actively negotiating material transfer agreements with other companies for collaborative research studies.
CEO Clarence Smith notes that the company has adequate cash on hand for project continuation and company operations for the near term.
About ProtoKinetix, Incorporated
ProtoKinetix is a molecular biotechnology company that has developed and patented a family of hyper stable, potent glycopeptides (AAGP®) that enhance both engraftment and protection of transplanted cells used in regenerative medicine. Due to the results achieved over the last four years of testing, the University of Alberta has begun Phase 1 human clinical trials. Additional studies will be expanded to include whole organ transplantation and all therapies that are being developed globally to date; diabetes, retinal degeneration, cardiac repair and many other degenerative conditions. In addition, we are studying the potential impact on several cancer therapies.
Cautionary Note Regarding Forward-Looking Statements
The information discussed in this press release includes “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933 (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act”). All statements, other than statements of historical facts, included herein concerning, among other things, planned capital expenditures, future cash flows and borrowings, pursuit of potential acquisition opportunities, our financial position, business strategy and other plans and objectives for future operations, are forward looking statements. These forward looking statements are identified by their use of terms and phrases such as “may,” “expect,” “estimate,” “project,” “plan,” “believe,” “intend,” “achievable,” “anticipate,” “will,” “continue,” “potential,” “should,” “could,” and similar terms and phrases. Although we believe that the expectations reflected in these forward looking statements are reasonable, they do involve certain assumptions, risks and uncertainties and are not (and should not be considered to be) guarantees of future performance. Among these risks are those set forth in a Form 10-K filed on February 21, 2017. It is important that each person reviewing this release understand the significant risks attendant to the operations of ProtoKinetix. ProtoKinetix disclaims any obligation to update any forward-looking statement made here.
For further information, please contact:
Clarence E. Smith
President and Chief Executive Officer
Telephone: 304-299-5070
Email: [email protected]
Twitter: @ProtoKinetix
ProtoKinetix, Inc.